Bayer, Regeneron commence EYLEA Phase 3 clinical trial for wet AMD in China

Editorial Checklist Reviewed
Regeneron Pharmaceuticals, Inc.Nov 28 2011NewsGuard 100/100 Score

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that they have initiated a Phase 3 clinical trial evaluating the efficacy and safety of EYLEA™ (aflibercept) Injection in the neovascular form of age-related macular degeneration (wet AMD) in China.

The new trial, named SIGHT, will include approximately 300 patients and will be the largest retinal trial conducted in China.  SIGHT is being led by Bayer.

"Currently, only photodynamic therapy with verteporfin is approved as a treatment for wet AMD in China, and it is only approved for the subpopulation of patients with predominantly classic wet AMD," said Kemal Malik, M.D., Head of Global Development and member of the Bayer HealthCare Executive Committee.  "After reporting positive data from our large VIEW program in wet AMD, we look forward to potentially bringing this new treatment to patients with wet AMD in China."

Source:

Regeneron Pharmaceuticals, Inc.

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , , , , , , , , , , , , , , , ,

Comments (0)

Suggested Reading

Incorrect arm positioning inflates blood pressure readings, risking misdiagnosis
Ozempic effective for patients with chronic kidney damage
Higher diet quality associated with reduced risk of prostate cancer grade reclassification
Vitamin K2 reduces the frequency, intensity, and duration of nighttime leg cramps
Cognitive behavioral therapy shows promise for prolonged grief disorder
HEPA air purifiers fall short in cutting respiratory infections in aged-care facilities
Weight loss drug semaglutide may offer relief for knee arthritis pain
Semaglutide reduces urine albumin-to-creatinine ratio in overweight chronic kidney disease patients

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Matcha green tea enhances cognition and sleep in older adults